Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

655 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial.
Pozniak A, Markowitz M, Mills A, Stellbrink HJ, Antela A, Domingo P, Girard PM, Henry K, Nguyen T, Piontkowsky D, Garner W, White K, Guyer B. Pozniak A, et al. Among authors: girard pm. Lancet Infect Dis. 2014 Jul;14(7):590-9. doi: 10.1016/S1473-3099(14)70796-0. Epub 2014 Jun 5. Lancet Infect Dis. 2014. PMID: 24908550 Clinical Trial.
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
Kinloch-de Loes S, Hoen B, Smith DE, Autran B, Lampe FC, Phillips AN, Goh LE, Andersson J, Tsoukas C, Sonnerborg A, Tambussi G, Girard PM, Bloch M, Battegay M, Carter N, El Habib R, Theofan G, Cooper DA, Perrin L; QUEST Study Group. Kinloch-de Loes S, et al. Among authors: girard pm. J Infect Dis. 2005 Aug 15;192(4):607-17. doi: 10.1086/432002. Epub 2005 Jul 15. J Infect Dis. 2005. PMID: 16028129 Clinical Trial.
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
Yeni P, Lamarca A, Berger D, Cimoch P, Lazzarin A, Salvato P, Smaill FM, Teofilo E, Madison SJ, Nichols WG, Adkison KK, Bonny T, Millard J, McCarty D; EPIC (CCR100136) study team. Yeni P, et al. HIV Med. 2009 Feb;10(2):116-24. doi: 10.1111/j.1468-1293.2008.00660.x. HIV Med. 2009. PMID: 19200175 Free article. Clinical Trial.
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Moyle GJ, Andrade-Villanueva J, Girard PM, Antinori A, Salvato P, Bogner JR, Hay P, Santos J, Astier L, Pans M, Balogh A, Biguenet S; ReAL Study Team. Moyle GJ, et al. Among authors: girard pm. Antivir Ther. 2012;17(4):689-700. doi: 10.3851/IMP2083. Epub 2012 Mar 2. Antivir Ther. 2012. PMID: 22388634 Clinical Trial.
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients.
Boyd A, Miailhes P, Brichler S, Scholtès C, Maylin S, Delaugerre C, Chevallier-Queyron P, Gordien E, Girard PM, Lacombe K. Boyd A, et al. Among authors: girard pm. AIDS Res Hum Retroviruses. 2013 Dec;29(12):1535-40. doi: 10.1089/AID.2013.0008. Epub 2013 Sep 24. AIDS Res Hum Retroviruses. 2013. PMID: 23972039 Free PMC article.
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, Delfraissy JF, Vella S, Chêne G, Pozniak A; NEAT001/ANRS143 Study Group. Raffi F, et al. Lancet. 2014 Nov 29;384(9958):1942-51. doi: 10.1016/S0140-6736(14)61170-3. Epub 2014 Aug 4. Lancet. 2014. PMID: 25103176 Clinical Trial.
Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years.
Gazzard B, Girard PM, Di Perri G, Gallant J, Towner W, Rogatto F, Demorin J, McColl D, Liu H, Rhee M, Szwarcberg J, Piontkowsky D. Gazzard B, et al. Among authors: girard pm. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19767. doi: 10.7448/IAS.17.4.19767. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397511 Free PMC article.
655 results